💡 Celebrating the International Day of Women and Girls in Science! 💡
February 11, 2025
Today, Pharmidex proudly honors the incredible contributions of women and girls in science who drive innovation, discovery, and progress in healthcare and beyond.
Their dedication, expertise, and passion are essential in shaping the future of drug discovery, development, and scientific breakthroughs.
We are committed to promoting diversity, inclusion, and equal opportunities, ensuring that the next generation of female scientists continues to thrive and make a lasting impact.
Let’s celebrate, support, and inspire more women and girls to pursue careers in science! 🌍🔬✨
#Pharmidex #WomenInScience #GirlsInSTEM #Innovation #DiversityInSTEM #ScienceForAll
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
